Spotlight On... China's FDA urged to get track-and-trace system in place; Ajinomoto Althea adding 50 jobs at California plant; FDA warns compounder Chemolee; and more...

Chinese drug companies are urging the country's Food and Drug Administration to act quickly to replace a supplier for a track-and-trace system there. The FDA recently put its project on hold after companies complained that its contract with a unit of Alibaba Group ($BABA) to design the barcode tracking system gave the Hong Kong-based company an unfair edge as it moves to fulfill its online drug selling ambitions. "I advise the CFDA to introduce a new tracking system with more detailed columns … and please be as quick as possible," Wei Feiyan, board chairwoman of Guangxi-based Huahong Pharmaceutical and a deputy to National People's Congress, said at an annual legislative meeting of Chinese leadership where health policy was discussed. More from FiercePharmaAsia

> The FDA has issued a warning letter against compounder Chemolee Lab in Irving, TX. Letter

> San Diego, CA-based Ajinomoto Althea is hiring at least 50 people to staff a second shift at its biologics manufacturing plant. Release

> American Airlines Cargo has added storage space to its pharma cold-chain facilities at the Dallas/Fort Worth airport.  Report

> Indonesia has opened its first bonded logistics center which will allow pharmaceutical ingredient makers, and other industries, store products for up to three years without paying taxes. Release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.